Whether this company clears the published standards, and the filings behind that answer. The screen runs first and nothing on the trading side can override it.
Structure, momentum, positioning and levels. Separate from the Sharia verdict above, which this side never overrides.
Methodology breakdown not tracked for 9987.T yet — our own seven-methodology screen needs filed financials we do not have for this symbol. The verdict above is our compliance provider's, unchanged.
Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.
Not tracked for 9987.T yet — our own seven-methodology screen runs off filed financials, and we do not have them for this symbol. The verdict above is our compliance provider's, unchanged and not affected by this.
Computed from published company financials, balance sheet as of 2026-03-31. 9987.T files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing investments | 40.75% | 30.00% | Fail |
| Non-permissible income | 0.01% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing investments | 12.26% | 33.00% | Pass |
| Non-liquid assets | 39.79% | at least 20.00% | Pass |
| Non-permissible income | 0.01% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 12.26% | 33.33% | Pass |
| Accounts receivable | 60.21% | 33.33% | Fail |
| Non-permissible income | 0.01% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 12.26% | 33.33% | Pass |
| Accounts receivable | 60.21% | 50.00% | Fail |
| Non-permissible income | 0.01% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 39.78% | 33.00% | Fail |
| Accounts receivable | 155.60% | 33.00% | Fail |
| Non-permissible income | 0.01% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 40.73% | 49.00% | Pass |
| Accounts receivable | 159.35% | 49.00% | Fail |
| Non-permissible income | 0.01% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 40.73% | 33.33% | Fail |
| Accounts receivable | 200.08% | 49.00% | Fail |
| Non-permissible income | 0.01% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Read from 9987.T's own filings. Every percentage on this page is one of these lines divided by another, so the inputs are shown rather than asserted.
| Line | Figure | As reported | Read from |
|---|---|---|---|
| RevenueTotal revenue for the period | $15.6B | 2026-03-31 | yahoo:annualTotalRevenue |
| Interest-bearing debtBorrowings — which definition was stored is not recorded | not measured | — | — |
| Cash and interest-bearing securitiesCash, equivalents and marketable securities | $888.3M | 2026-03-31 | yahoo:annualCashCashEquivalentsAndShortTermInvestments |
| Total assetsBalance sheet total | $7.2B | 2026-03-31 | yahoo:annualTotalAssets |
| Market capDenominator for AAOIFI | $2.2B | — | — |
| 36-month average market capDenominator for S&P Shariah and MSCI M-Series | not measured | — | — |
| 24-month average market capDenominator for Dow Jones Islamic Market | $2.3B | — | — |
| Non-permissible revenueInterest and excluded income | $990.7K | 2026-03-31 | yahoo:annualInterestIncome |
Two dates, not one: a balance-sheet line and an income-statement line cover different windows by design, so each figure carries its own.
Verdict history for 9987.T. A verdict that never moved is recorded too, so a quiet history reads as measured rather than missing.
Tracked since 2026-09-07.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 60.90 | NEUTRAL |
| Stochastic %K (14) | 73.44 | NEUTRAL |
| CCI (20) | 181.86 | SELL |
| Williams %R (14) | -26.56 | NEUTRAL |
| MACD (12,26,9) | 13.17 | BUY |
| ROC (10) | 2.79 | BUY |
| Momentum (10) | 144.00 | BUY |
| EMA (10) | 5236.59 | BUY |
| SMA (10) | 5220.10 | BUY |
| EMA (20) | 5190.19 | BUY |
| SMA (20) | 5179.05 | BUY |
| EMA (30) | 5163.01 | BUY |
| SMA (30) | 5123.57 | BUY |
| EMA (50) | 5151.75 | BUY |
| SMA (50) | 5111.34 | BUY |
| EMA (100) | 5245.05 | BUY |
| SMA (100) | 5137.96 | BUY |
| EMA (200) | 5546.72 | SELL |
| SMA (200) | 5632.53 | SELL |
Healthcare · Medical Distribution
Suzuken Co., Ltd., together with its subsidiaries, primarily engages in the distribution of pharmaceuticals in Japan and internationally. The company operates in four segments: Pharmaceutical Distribution, Healthcare Product Development, Community Healthcare and Nursing Care Support, Specialty Drug Contract Distribution, and Healthcare Related Services. The Pharmaceutical Distribution Business segment purchases ethical drugs, diagnostic agents, medical equipment, medical materials, and medical food products, as well as pharmaceutical and medical equipment manufacturers, and supplies medical institutions, and insurance pharmacies. The Healthcare Product Development segment offers ethical drugs, diagnostic reagents, and medical devices and materials. The Community Healthcare and Nursing Care Support segment provides a range of pharmacy and nursing care services. The Healthcare Related Services segment offers contract distribution for manufacturers and contract distribution of orphan drugs. Suzuken Co., Ltd. was founded in 1932 and is headquartered in Nagoya, Japan.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2026-03-31, figures in JPY.
Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.
Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.
How the rest of the sector moved over the same window. Context for a price move, never a cause of one.
Peer movement computing — it will appear here on its own.
The questions worth asking about any verdict on this page, answered plainly.
No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.
Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.
Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.
If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from.
Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.
Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.
Peer screening computing — it will appear here on its own.
Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.
NO DATA 0 buys · 0 sells
The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.